Digestive Diseases and Sciences

, Volume 55, Issue 6, pp 1533–1539 | Cite as

Aspirin Use and the Risk of Gastric Cancer: A Meta-Analysis

  • Ping Yang
  • Yong Zhou
  • Bo Chen
  • Hong-Wei Wan
  • Gui-Qing Jia
  • Hai-Long Bai
  • Xiao-Ting WuEmail author



Studies investigating the association between aspirin use and gastric cancer risk have reported conflicting results. The objective of this study was to quantitatively summarize the evidence for such a relationship.


Two investigators independently searched the Medline, PubMed, Embase, and Academic Search Premier (EBSCO) databases. Fourteen studies with a total number of 5,640 gastric cancer cases were identified. Most of the study populations were Caucasian. The combined results based on all studies showed there was no statistically significant difference between aspirin use and gastric cancer risk (odds ratio (OR) = 0.80, 95% confidence intervals (CI) = 0.54–1.19). When stratifying by study designs and gender, results were similar except for cohort and randomized controlled trial (RCT) studies (OR = 0.72, 95% CI = 0.62–0.84). When stratifying by location and Helicobacter pylori (H. pylori) infection, we observed there were lower risks in noncardia gastric cancer (OR = 0.62, 95% CI = 0.55–0.69) and H. pylori-infected individuals (OR = 0.62, 95% CI = 0.42–0.90) for aspirin users. Among Caucasians, there were lower risks for noncardia gastric cancer (OR = 0.73, 95% CI = 0.62–0.87) and H. pylori-infected individuals (OR = 0.62, 95% CI = 0.42–0.90) also.


This meta-analysis indicated that regular use of aspirin may be associated with reduced risk of noncardia gastric cancer, especially among Caucasians; for H. pylori-infected subjects the result was similar.


Aspirin Gastric cancer Helicobacter pylori Meta-analysis 


Conflict of Interest Statement

We declare that no conflict of interest exists for any of the authors.


  1. 1.
    Paking DM, Bray F, Ferlay J, Pissani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefGoogle Scholar
  2. 2.
    Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–477.CrossRefPubMedGoogle Scholar
  3. 3.
    Clapp RW, Jacobs MM, Loechler EL. Environment and occupational cause of cancer: new evidence 2005–2007. Rev Environ Health. 2008;23:1–37.PubMedGoogle Scholar
  4. 4.
    Lim HY, Joo HJ, Yi JW, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519–525.PubMedGoogle Scholar
  5. 5.
    Joo YE, Chung IJ, Park YS, et al. Expression of cyclooxygenase-2, p53 and ki-67 in gastric cancer. J Korean Med Sci. 2006;21:871–876.CrossRefPubMedGoogle Scholar
  6. 6.
    Tong Q, Wang G, Lu X, Tao K, Chen D. Expression and clinical significance of nuclear factor-kB and cyclooxygenase-2 in gastric carcinoma tissue. Chin J Gastroenterol. 2006;11:160–163.Google Scholar
  7. 7.
    Hou L, Grillo P, Zhu ZZ, et al. COX-1 and COX-2 polymorphisms and gastric cancer risk in a Polish population. Anticancer Res. 2007;27:4234–4247.Google Scholar
  8. 8.
    Redlak MJ, Power JJ, Miller TA. Aspirin-induced apoptosis in human gastric cancer epithelial cells: relationship with protein kinase C signaling. Dig Dis Sci. 2007;52:810–816.CrossRefPubMedGoogle Scholar
  9. 9.
    Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999;79:1469–1477.PubMedGoogle Scholar
  10. 10.
    Oba M, Miwa K, Fujimura T, Harada S, Sasaki S, Hattori T. Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor. Int J Cancer. 2008;123:1491–1498.CrossRefPubMedGoogle Scholar
  11. 11.
    Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with non-steroidal anti-inflammatory drugs. Cancer. 2002;94:950–963.CrossRefPubMedGoogle Scholar
  12. 12.
    Redlak MJ, Power JJ, Miller TA. Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kB and PKC signaling. J Surg Res. 2008;145:66–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Jolly K, Cheng KK, Langman MJ. NSAIDs and gastrointestinal cancer prevention. Drugs. 2002;62:945–956.CrossRefPubMedGoogle Scholar
  14. 14.
    Husain SS, Szabo IL, Tamawski AS. NSAIDs inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol. 2002;97:542–553.CrossRefPubMedGoogle Scholar
  15. 15.
    Gammon MD, Terry MB, Arber N, et al. Non-steroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of esophagus and gastric cardia that over express cyclin D1: a population-based study. Cancer Epidemiol Biomark Prev. 2004;13:34–39.CrossRefGoogle Scholar
  16. 16.
    Hwang HJ, Youn YH, Kim JH, Chung JB, Lee YC. Low-dose aspirin affects the clinicopathological features of gastric cancer. Digestion. 2006;73:54–59.CrossRefPubMedGoogle Scholar
  17. 17.
    Jonge PJF, Wolters LMM, Steyerberg EW, et al. Environmental risk factors in the development of adenocarcinoma of the oesophagus or gastric cardia: a cross-sectional study in Dutch cohort. Aliment Pharmacol Ther. 2007;26:31–39.Google Scholar
  18. 18.
    Giliies M, Skyring A. Gastric ulcer, duodenal ulcer and gastric carcinoma: a case-control study of certain social and environmental factors. Med J Aust. 1968;2:1132–1136.Google Scholar
  19. 19.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Health CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322–1327.PubMedGoogle Scholar
  20. 20.
    Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138–146.CrossRefPubMedGoogle Scholar
  21. 21.
    Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomark Prev. 1998;7:97–102.Google Scholar
  22. 22.
    Zaridze D, Borisova E, Maximovitich D, Chkhikvadze V. Aspirin protects against gastric cancer: result of a case-control study from Moscow, Russia. Int J Cancer. 1999;82:473–476.CrossRefPubMedGoogle Scholar
  23. 23.
    Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer. 2001;84:965–968.CrossRefPubMedGoogle Scholar
  24. 24.
    Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24:3177–3184.PubMedGoogle Scholar
  25. 25.
    Lindblad M, Lagergren J, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomark Prev. 2005;14:444–450.CrossRefGoogle Scholar
  26. 26.
    Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the women’s health study: a randomized controlled trial. JAMA. 2005;294:47–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Fortuny J, Johnson C, Bohlke K, et al. Use of anti-inflammatory drugs and lower esophageal sphincter relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007;5:1154–1159.CrossRefPubMedGoogle Scholar
  28. 28.
    Duan L, Wu AH, Sullivan Halley J, Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomark Prev. 2008;17:126–134.CrossRefGoogle Scholar
  29. 29.
    Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC. Aspirin, non-steroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomark Prev. 2008;17:1169–1178.CrossRefGoogle Scholar
  30. 30.
    Abnet CC, Freendman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009;100:551–557.CrossRefPubMedGoogle Scholar
  31. 31.
    Figueroa JD, Terry MB, Gammon MD, et al. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control. 2009;20:361–368.CrossRefPubMedGoogle Scholar
  32. 32.
    Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medication: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48:4399–4404.PubMedGoogle Scholar
  33. 33.
    Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf. 2008;17:115–124.CrossRefPubMedGoogle Scholar
  34. 34.
    Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008;100:1439–1447.CrossRefPubMedGoogle Scholar
  35. 35.
    Liu E, Sakodal LC, Gao YT, et al. Aspirin use and risk of biliary tract cancer: a population-based study in Shanghai, China. Cancer Epidemiol Biomark Prev. 2005;14:1315–1318.CrossRefGoogle Scholar
  36. 36.
    Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J. 2006;12:130–135.PubMedGoogle Scholar
  37. 37.
    Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS, Schwartz AG. Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomark Prev. 2008;17:148–157.CrossRefGoogle Scholar
  38. 38.
    Morales TG. Adenocarcinoma of the gastric cardia. Dig Dis. 1997;15:346–356.CrossRefPubMedGoogle Scholar
  39. 39.
    Maeda H, Okabayashi T, Nishimori I, et al. Clincopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206:306–310.CrossRefPubMedGoogle Scholar
  40. 40.
    Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risk of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006;98:1445–1452.PubMedCrossRefGoogle Scholar
  41. 41.
    Tatemichi M, Sasazuki S, Inoue M, Tsugane S. Different etiological role of Helicobacter pylori (Hp) infection in carcinogenesis between differentiated and undifferentiated gastric cancers: a nest case-control study using IgG titer against Hp surface antigen. Acta Oncol. 2008;47:360–365.CrossRefPubMedGoogle Scholar
  42. 42.
    Tally NJ. Is it time to screen, treat H. pylori to prevent gastric cancer? Lancet. 2008;372:350–352.CrossRefGoogle Scholar
  43. 43.
    Wang WH, Wong WM, Dailidiene D, et al. Aspirin inhibits the growth of Helicobacter pylori enhances its susceptibility to antimicrobial agents. Gut. 2003;52:490–495.CrossRefPubMedGoogle Scholar
  44. 44.
    Takahashi M, Katayama Y, Takada H, Kuwayama H, Terano A. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther. 2004;14(Suppl 1):44–49.Google Scholar
  45. 45.
    Wacholder S, Mclaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies I. Principles. Am J Epidemiol. 1992;135:1019–1028.PubMedGoogle Scholar
  46. 46.
    Patterson RE, Neuhouser ML, White E, Hunt JR, Kristal AR. Cancer-related behavior of vitamin supplement users. Cancer Epidemiol Biomark Prev. 1998;7:79–81.Google Scholar
  47. 47.
    Sample DA, Sinicrope PS, Wargovich MJ, Sinicrope FA. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomark Prev. 2002;11:281–285.Google Scholar
  48. 48.
    Ryár I, Hlísta M, Masark P, et al. Gastroduodenal complication associated with non-steroidal anti-inflammatory drugs in Slovak Republic: result of one-year prospective study. Vnitr Lek. 2006;52:673–676.Google Scholar
  49. 49.
    Ishikawa S, Inaba T, Mizuno M, et al. Incidence of serious upper gastrointestinal bleeding in patients taking non-steroidal anti-inflammatory drugs in Japan. Acta Med Okayama. 2008;62:29–36.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ping Yang
    • 1
  • Yong Zhou
    • 1
  • Bo Chen
    • 1
  • Hong-Wei Wan
    • 1
  • Gui-Qing Jia
    • 1
  • Hai-Long Bai
    • 1
  • Xiao-Ting Wu
    • 1
    Email author
  1. 1.Department of Gastrointestinal Surgery, West China HospitalSichuan UniversityChengduChina

Personalised recommendations